Randomized, open-label, dose-ranging study of dabigatran, a novel, oral, direct thrombin inhibitor, in elective PCI (the D-fine study) (abstract O-TH-032) - Leebeek, FWG; de Maat, M P; Jones, R (J Thromb Haemost, 2011)
et al.